Silexion Therapeutics (NASDAQ:SLXN) Shares Down 7.2% – Here’s Why

Silexion Therapeutics Corp (NASDAQ:SLXN) shares were down 7.2% on Friday . The company traded as low as $2.48 and last traded at $2.58. Approximately 7,291 shares changed hands during trading, a decline of 85% from the average session volume of 47,613 shares. The stock had previously closed at $2.78.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Silexion Therapeutics Price Performance

The stock’s 50 day simple moving average is $3.56 and its two-hundred day simple moving average is $11.24. The firm has a market cap of $1.08 million, a P/E ratio of -0.03 and a beta of -0.26.

Silexion Therapeutics (NASDAQ:SLXN) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($12.90) by $12.05. Equities research analysts anticipate that Silexion Therapeutics Corp will post -45.5 earnings per share for the current year.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.